Simplifying Global Compliance
Lilly and BI Insulin Biosimilar Wins Positive CHMP Recommendation
A key European panel has recommended approval for Eli Lilly and Boehringer Ingelheim’s biosimilar of Sanofi’s blockbuster long-acting insulin drug Lantus, creating a potential threat to the French drugmaker’s multi-billion dollar product.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing